Riad Salem, MD

Expert Riad Salem, MD, MBA, highlights key data from the phase 3 EPOCH study, which evaluated TheraSphere in patients with mCRC and liver metastases who failed first line chemotherapy.

Riad Salem, MD, discusses the history of TheraSphere™ Yttrium-90 in metastatic colorectal cancer.

Riad Salem, MD, discusses outcomes with TheraSphere™ Yttrium-90 Glass Microsphere as a bridging therapy prior to transplantation in hepatocellular carcinoma.

Riad Salem, MD, discusses considerations for selecting the appropriate treatment approach for patients with hepatocellular carcinoma.

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Riad Salem, MD, discusses the role of locoregional therapy in hepatocellular carcinoma.

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.